Date published: 2026-5-30

1-800-457-3801

SCBT Portrait Logo
Seach Input

SLC17A (solute carrier family 17) Inhibitors

The SLC17A (solute carrier family 17) family comprises a group of membrane transport proteins that play key roles in the transport of a variety of substrates, including organic anions, phosphates, and neurotransmitters. Members of this family are primarily known as phosphate transporters (SLC17A1-4) and vesicular glutamate transporters (VGLUTs, SLC17A5-7). The phosphate transporters are involved in the renal reabsorption of phosphate, a critical process for maintaining phosphate homeostasis, bone mineralization, and overall metabolic function. The VGLUTs are crucial in the central nervous system, where they transport glutamate into synaptic vesicles, facilitating excitatory neurotransmission. The signaling and function of SLC17A transporters are essential in various physiological processes, from bone health to nerve communication, and their dysfunction is implicated in several diseases, including neurological disorders and phosphate metabolism abnormalities.

Targeting SLC17A signaling for disruption or inhibition with small molecules enables a more detailed understanding of the diverse roles these transporters play in physiological and pathological processes. By inhibiting specific SLC17A transporters, researchers can delineate their individual contributions to phosphate homeostasis and neurotransmitter regulation. Such targeted approaches are crucial in elucidating the mechanisms of diseases related to phosphate imbalance or glutamate signaling disorders. Additionally, the use of small molecule inhibitors can shed light on the potential targets within the SLC17A family for conditions like osteoporosis or neurodegenerative diseases.

SEE ALSO...

Items 1 to 10 of 23 total

Display:

Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

6-Nitro-7-sulfamoylbenzo[f]quinoxaline-2,3-Dione

118876-58-7sc-478080
5 mg
$70.00
1
(0)

NBQX is an AMPA receptor antagonist, which can indirectly affect glutamate signaling and release.

D(−)-2-Amino-5-phosphonovaleric acid (D-AP5)

79055-68-8sc-200434
5 mg
$97.00
2
(1)

As an NMDA receptor antagonist, AP5 can indirectly influence glutamate signaling and release.

6-Cyano-7-nitroquinoxaline-2,3-dione

115066-14-3sc-505104
10 mg
$208.00
2
(0)

CNQX is a potent AMPA receptor antagonist, indirectly affecting glutamate signaling and release.

Kynurenic acid

492-27-3sc-202683
sc-202683A
sc-202683B
250 mg
1 g
5 g
$26.00
$57.00
$138.00
6
(1)

This is a broad-spectrum antagonist for excitatory amino acid receptors, thus reducing glutamate signaling.

Riluzole

1744-22-5sc-201081
sc-201081A
sc-201081B
sc-201081C
20 mg
100 mg
1 g
25 g
$20.00
$193.00
$213.00
$317.00
1
(1)

Riluzole inhibits the release of glutamate, influencing the function of SLC17A7 indirectly.

Memantine hydrochloride

41100-52-1sc-203628
50 mg
$69.00
4
(2)

This is an NMDA receptor antagonist, indirectly affecting glutamate signaling.

Ethosuximide

77-67-8sc-211431
1 g
$306.00
(0)

This compound reduces T-type calcium channel activity, which can indirectly influence glutamate release.

Lamotrigine

84057-84-1sc-201079
sc-201079A
10 mg
50 mg
$120.00
$486.00
1
(1)

Lamotrigine inhibits voltage-sensitive sodium channels, leading to a decrease in glutamate release.

Topiramate

97240-79-4sc-204350
sc-204350A
10 mg
50 mg
$107.00
$369.00
(1)

It modulates GABA-evoked currents, indirectly influencing glutamate release.

Felbamate

25451-15-4sc-203579
sc-203579A
10 mg
50 mg
$101.00
$373.00
(0)

Felbamate acts as a NMDA receptor antagonist, indirectly affecting glutamate signaling and release.